154 related articles for article (PubMed ID: 28192480)
1. mTOR activity in AIDS-related diffuse large B-cell lymphoma.
Browne SH; Diaz-Perez JA; Preziosi M; King CC; Jones GA; Jain S; Sun X; Reid EG; VandenBerg S; Wang HY
PLoS One; 2017; 12(2):e0170771. PubMed ID: 28192480
[TBL] [Abstract][Full Text] [Related]
2. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
3. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
[TBL] [Abstract][Full Text] [Related]
6. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
Kim HS; Kim GY; Lim SJ; Kim YW
Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
8. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.
Wang W; Wen Q; Xu L; Xie G; Li J; Luo J; Chu S; Shi L; Huang D; Li J; Fan S
PLoS One; 2014; 9(8):e106098. PubMed ID: 25165983
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
10. [Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].
Li JF; Li GD; Gu L; Liu WP; Li FY; Liao DY; Ma ZG
Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):649-53. PubMed ID: 19176054
[TBL] [Abstract][Full Text] [Related]
11. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
Márk Á; Hajdu M; Váradi Z; Sticz TB; Nagy N; Csomor J; Berczi L; Varga V; Csóka M; Kopper L; Sebestyén A
BMC Cancer; 2013 May; 13():250. PubMed ID: 23693095
[TBL] [Abstract][Full Text] [Related]
12. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray.
Xiao L; Wang YC; Li WS; Du Y
J Exp Clin Cancer Res; 2009 Dec; 28(1):152. PubMed ID: 20003385
[TBL] [Abstract][Full Text] [Related]
13. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
15. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
Liontos M; Trigka EA; Korkolopoulou P; Tzannis K; Lainakis G; Koutsoukos K; Kostouros E; Lykka M; Papandreou CN; Karavasilis V; Christodoulou C; Papatsoris A; Skolarikos A; Varkarakis I; Adamakis I; Alamanis C; Stravodimos K; Mitropoulos D; Deliveliotis C; Constantinidis CA; Saetta A; Patsouris E; Dimopoulos MΑ; Bamias A
World J Urol; 2017 Mar; 35(3):411-419. PubMed ID: 27395374
[TBL] [Abstract][Full Text] [Related]
17. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
18. Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.
Sebestyén A; Sticz TB; Márk A; Hajdu M; Timár B; Nemes K; Nagy N; Váradi Z; Kopper L
Mod Pathol; 2012 Dec; 25(12):1623-8. PubMed ID: 22899290
[TBL] [Abstract][Full Text] [Related]
19. Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma.
Li N; Zhong M; Song M
Int J Clin Exp Pathol; 2012; 5(7):660-7. PubMed ID: 22977662
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
